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Background:  Elderly patients with ACS are at increased risk of both ischemic events and bleeding. We investigated the efficacy and safety of the 
novel, intravenous factor Xa inhibitor otamixaban (OTAM) compared to unfractionated heparin (UFH)+eptifibatide in these high risk patients.
Methods:  We compared the effect of OTAM vs. UFH+eptifibatide on efficacy (death/MI) and safety (TIMI non-CABG major/minor bleeding) through 
7 d in NSTE-ACS patients in SEPIA-ACS1 TIMI 42, focusing on the 2 doses of OTAM (0.105 & 0.140 mg/kg/h) similar to those being carried forward 
in the phase 3 trial and stratifying patients by age <75 (n=1517) and ≥75 (n=252).
Results:  Overall, patients ≥75 y were at significantly increased risk of death/MI (RR 1.93, p=0.0032) and of bleeding (RR 2.66, p<0.0001). In all 
patients, the 0.105 and 0.104 mg/kg/h doses of OTAM combined significantly reduced death/MI (RR 0.54, P=0.02) without increasing bleeding (RR 
1.20, P=0.56) compared to UFH+eptifibatide. The magnitude of the efficacy of OTAM in reducing death/MI (Fig Left) was preserved regardless of age 
(Pinteraction=0.50 & 0.98) as was the safety (Fig Right; Pinteraction=0.51 & 0.29), with numerically lower rates of bleeding in the elderly with OTAM.
Conclusions:  The doses of OTAM being carried forward in the ongoing phase 3 TAO trial appear to offer a particularly attractive alternative to 
UFH+eptifibatide in the elderly with a favorable efficacy and safety profile in a population at heightened risk of both ischemic events and bleeding.
